Does Cabergoline Cause Impulse Control Disorders?
At a Glance
Prolactinoma medications like cabergoline can cause impulse control disorders, leading to compulsive gambling, shopping, or hypersexuality. This is a reversible neurological side effect, not a character flaw. Contact your endocrinologist to safely adjust your dose; never stop cold turkey.
In this answer
5 sections
Yes, your prolactinoma medication can cause behavioral changes. Medications used to treat prolactinomas, such as cabergoline and bromocriptine, can cause a significant behavioral side effect known as an impulse control disorder (ICD) [1]. This can manifest as compulsive gambling, excessive shopping, hypersexuality, or binge eating [2]. If you or a loved one are experiencing these urges, it is crucial to understand that this is a recognized neurological side effect of the medication—not a personal failing or a permanent change in your character [1][3]. While these side effects are more commonly discussed in Parkinson’s disease where dopamine agonist doses are much higher, they still affect a significant number of prolactinoma patients [4][5].
Why Does This Happen?
Prolactinomas are typically treated with dopamine agonists [6]. These drugs work by mimicking dopamine, a natural chemical in your brain, to suppress prolactin production and shrink the tumor [7]. However, dopamine is also the primary chemical involved in your brain’s reward and pleasure pathways.
When a medication over-stimulates these reward pathways, it can cause them to become overactive. This leads to intense, uncontrollable urges to engage in highly rewarding behaviors, even when those behaviors have negative consequences [3][8].
What Do Impulse Control Disorders Look Like?
Research suggests that up to 1 in 6 patients taking dopamine agonists for a prolactinoma may develop an impulse control disorder [1]. Symptoms often appear shortly after starting the medication or increasing the dose [9], though they can develop at any time.
- Pathological gambling: An uncontrollable urge to gamble, which can rapidly lead to severe financial distress [10].
- Hypersexuality: An unusual and intense increase in sexual thoughts, urges, or behaviors [2].
- Compulsive shopping: Spending money excessively on unneeded items or in ways that cause financial strain [2].
- Compulsive eating or punding: Binge eating or engaging in repetitive, purposeless tasks (like taking things apart and putting them back together, known as punding) [11][12].
A Note for Family and Partners: A key feature of these disorders is that the patient often lacks insight into their own behavioral changes, or they actively hide the behavior due to intense shame. Because the reward pathway is hijacked, the patient may feel their behavior is completely justified. Family members and partners are often the first to notice these changes. Recognizing this as a medical side effect—not a personal betrayal—is the first step toward finding a solution.
Who is at Risk?
While anyone taking these medications can develop an ICD, certain factors may increase your risk:
- Male sex: Men are statistically more likely to develop ICDs from these medications [9][1]. In men, hypersexuality is particularly common as the medication successfully restores normal testosterone levels (a process sometimes referred to as “dopa-testotoxicosis”) [13].
- Higher doses: The risk is generally dose-dependent, meaning higher doses of cabergoline increase the likelihood of developing these behaviors [9][14].
- Personal history: A previous history of psychiatric disorders, gambling, smoking, or alcohol use can make someone more susceptible [12][15].
Will This Go Away?
Yes. The most important thing to know is that these behavioral changes are reversible. When the dopamine agonist is lowered, switched to a different medication, or stopped entirely, the compulsive urges typically begin to resolve within days to weeks [16][17].
Do not stop taking your medication cold turkey. Suddenly stopping your medication can allow your tumor to resume growing or your prolactin levels to quickly rebound. Instead, contact your endocrinologist immediately to safely adjust your treatment plan [10][18]. Lowering the dose, switching to another dopamine agonist, or exploring surgical options if medication cannot be tolerated, can resolve the issue without sacrificing tumor control [16][19].
How to Talk to Your Doctor
It is completely normal to feel deeply embarrassed or terrified to tell a doctor about a secret gambling problem or hypersexuality. However, endocrinologists are fully aware of this side effect. They will not judge you or think you are “crazy”—they will recognize it as a chemical reaction to the medication.
If you are unsure how to start the conversation, try saying: “I am experiencing some distressing behavioral changes, like [mention symptom], and I read this might be a side effect of cabergoline. Can we discuss adjusting my medication?”
Common questions in this guide
Can prolactinoma medications change my personality or behavior?
Will cabergoline side effects like hypersexuality go away?
Should I stop taking cabergoline if I notice compulsive behaviors?
Who is at risk for developing an impulse control disorder from dopamine agonists?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Is my current dose the lowest effective dose for controlling my prolactinoma?
- 2.Would switching from cabergoline to bromocriptine (or vice versa) help reduce these behavioral urges?
- 3.Am I a candidate for surgical removal of the tumor instead of continuing medication if these side effects are intolerable?
- 4.How should I safely taper down my medication if we decide to change my treatment plan?
- 5.Are there other behavioral or mood side effects, like anxiety or irritability, that my family and I should watch for?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (19)
- 1
Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.
Dogansen SC, Cikrikcili U, Oruk G, et al.
The Journal of clinical endocrinology and metabolism 2019; (104(7)):2527-2534 doi:10.1210/jc.2018-02202.
PMID: 30848825 - 2
Adverse events associated with four atypical antipsychotics used as augmentation treatment for major depressive disorder: A pharmacovigilance study based on the FAERS database.
Qi F, Tian L, Diao H, et al.
Journal of affective disorders 2025; (388()):119435 doi:10.1016/j.jad.2025.119435.
PMID: 40449747 - 3
A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients With Prolactinoma.
Sahin S, Sudutan T, Kavla Y, et al.
The Journal of clinical endocrinology and metabolism 2023; (108(6)):e275-e282 doi:10.1210/clinem/dgac718.
PMID: 36494095 - 4
Impulse Control Disorders in Southern Iraqi Patients Medicated With Cabergoline for Prolactinoma.
Mohammad MM, Alidrisi HA, Mansour AA
Cureus 2024; (16(4)):e58516 doi:10.7759/cureus.58516.
PMID: 38957818 - 5
Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors.
Contin M, Lopane G, Marini L, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(2)):565-572 doi:10.1007/s10072-022-06485-y.
PMID: 36350455 - 6
Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.
Celik E, Ozkaya HM, Poyraz BC, et al.
Endocrine 2018; (62(3)):692-700 doi:10.1007/s12020-018-1744-8.
PMID: 30206771 - 7
Giant Prolactinomas.
Shimon I
Neuroendocrinology 2019; (109(1)):51-56 doi:10.1159/000495184.
PMID: 30404098 - 8
Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off-target activity.
Suzuki T, Oana F, Oota M, et al.
British journal of pharmacology 2026; doi:10.1111/bph.70351.
PMID: 41578631 - 9
Cabergoline and impulse control disorders: Screening patients with pituitary adenomas in an endocrinology clinic.
Lydiatt M, Grissom B, Givens J, et al.
Journal of psychiatric research 2026; (195()):105-112 doi:10.1016/j.jpsychires.2026.01.041.
PMID: 41619686 - 10
Impulse control disorders in prolactinoma patients treated with dopamine agonists: a systematic review and meta-analysis with trial sequential analysis.
Penchev P, Milanova-Ilieva D, Gaydarski L, et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2025; (138()):111363 doi:10.1016/j.jocn.2025.111363.
PMID: 40480033 - 11
Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors.
De Sousa SMC, Baranoff J, Rushworth RL, et al.
The Journal of clinical endocrinology and metabolism 2020; (105(3)) doi:10.1210/clinem/dgz076.
PMID: 31580439 - 12
Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study.
Almalki MH, Alsuraikh MA, Almalki E, et al.
Pituitary 2024; (27(2)):197-203 doi:10.1007/s11102-024-01383-2.
PMID: 38345719 - 13
Hypersexuality in men with prolactinomas treated with dopamine agonists.
Bancos I, Nippoldt TB, Erickson D
Endocrine 2017; (56(3)):456-457 doi:10.1007/s12020-017-1247-z.
PMID: 28160129 - 14
Subthalamic nucleus deep brain stimulation and impulsivity in Parkinson's disease: a descriptive review.
Lo Buono V, Lucà Trombetta M, Palmeri R, et al.
Acta neurologica Belgica 2021; (121(4)):837-847 doi:10.1007/s13760-021-01684-4.
PMID: 33961279 - 15
Prevalence and Risk Factors of Dopamine Agonists Induced Impulse Control Disorders in Patients With Prolactinoma.
Zhang S, Wang C, Wang D
International journal of psychiatry in medicine 2025; 912174251392426 doi:10.1177/00912174251392426.
PMID: 41165051 - 16
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study.
Fusaroli M, Giunchi V, Battini V, et al.
Psychiatry and clinical neurosciences 2023; (77(3)):160-167 doi:10.1111/pcn.13511.
PMID: 36436204 - 17
Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
De Sousa SM, Chapman IM, Falhammar H, Torpy DJ
Endocrine 2017; (55(2)):618-624 doi:10.1007/s12020-016-1088-1.
PMID: 27601019 - 18
Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.
Ioachimescu AG, Fleseriu M, Hoffman AR, et al.
European journal of endocrinology 2019; (180(1)):31-40.
PMID: 30400048 - 19
Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
Teixeira M, Souteiro P, Carvalho D
Pituitary 2017; (20(4)):464-470 doi:10.1007/s11102-017-0806-x.
PMID: 28523537
This page discusses behavioral side effects of prolactinoma medications for educational purposes only. Never stop taking your medication without first consulting your endocrinologist to safely adjust your treatment.
Get notified when new evidence is published on Prolactinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.